In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ActoGeniX NV

Division of Intrexon Corp.
www.actogenix.com

Latest From ActoGeniX NV

Strong Market For Regenerative Medicine Deals Drives Value

Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Regenerative Medicine Deals

Appointments: Promethera, HealthTell, Baxter, Alzheon, Gilead, Arena and Ligand

This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.

Appointments

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

BioPharmaceutical Innovation

Intrexon Buys Tools, Wins Partners

Intrexon’s acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Intrexon Corp.
  • Senior Management
  • Bernard Coulie, MD, PhD, CEO & CMO
    Luc Van fraeyenhoven, CFO
    Pieter Rottiers, PhD, VP, R&D
    Anjan Aralihalli, Chief Bus. Officer
    Magda Van Hijfte, Dir., Fin.
    Lothar Steidler, PhD, VP, Tech
    Emil Pot, LLM, EPA, General Counsel
    Decebal Bora, PharmD, Director, Reg Affairs
    Sabine Neirynck, PhD, Director, Lab Ops
  • Contact Info
  • ActoGeniX NV
    Phone: (32) (0)9 261 06 00
    Technologiepark 4
    Zwijnaarde, 9052
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register